The Gross Margin of Kura Oncology, Inc. (KURA) is
99.92%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date |
Value |
| 2025-12-31 |
99.92%
|
| Ticker |
Name |
Value |
|
AMGN
|
Amgen Inc
|
70.78%
|
|
CYTK
|
Cytokinetics, Incorporated
|
7775.20%
|
|
DMTK
|
DermTech Inc
|
1.80%
|
|
KNTE
|
Kinnate Biopharma Inc
|
7775.20%
|
|
KRON
|
Kronos Bio LLC
|
7775.20%
|
|
REPL
|
Replimune Group, Inc.
|
7775.20%
|
|
STOK
|
Stoke Therapeutics, Inc.
|
7775.20%
|
|
ALEC
|
Alector, Inc.
|
7775.20%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
86.24%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
86.56%
|
|
YMAB
|
Y-mAbs Therapeutics Inc
|
82.89%
|
|
GBIO
|
Generation Bio Co
|
7775.20%
|
|
OCGN
|
Ocugen, Inc.
|
7775.20%
|
|
CCCC
|
C4 Therapeutics, Inc.
|
7775.20%
|
|
ABBV
|
AbbVie Inc.
|
71.62%
|
|
ALVR
|
Allovir Inc
|
7775.20%
|
|
ARQT
|
Arcutis Biotherapeutics, Inc.
|
90.24%
|
|
KRYS
|
Krystal Biotech, Inc.
|
94.08%
|
|
PMVP
|
Pmv Pharmaceuticals, Inc
|
7775.20%
|
|
950200.KQ
|
Psomagen Inc
|
24.48%
|
|
MRNA
|
Moderna, Inc.
|
70.32%
|
|
GILD
|
Gilead Sciences, Inc.
|
78.84%
|
|
MYOV
|
Myovant Sciences Ltd
|
77.68%
|
|
OLMA
|
Olema Pharmaceuticals, Inc.
|
7775.20%
|
|
ZYME
|
Zymeworks Inc.
|
7775.20%
|
|
CGEM
|
Cullinan Therapeutics, Inc.
|
7775.20%
|
|
NKTX
|
Nkarta, Inc.
|
7775.20%
|
|
VBIV
|
VBI Vaccines Inc
|
-44.06%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
13.28%
|
|
IMVT
|
Immunovant, Inc.
|
7775.20%
|
|
MCRB
|
Seres Therapeutics, Inc.
|
7775.20%
|
|
NRIX
|
Nurix Therapeutics, Inc.
|
7775.20%
|
|
STTK
|
Shattuck Labs Inc
|
7775.20%
|
|
950220.KQ
|
Neoimmunetech Inc
|
7775.20%
|